Abiopharma

🔍 Sullivan Brian F. (Executive)

Company: Celcuity Inc. (CELC)

Report Date: 2026-08-14

Detailed Transactions and Holdings:

• Acquired 80,000 shares of Common Stock (Direct)
  Date: 2026-08-14 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,450,199.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-14 | Code: H | nature_of_ownership: By Family Trust #1 | shares_owned_after: 948,042.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-14 | Code: H | nature_of_ownership: By Family Trust #2 | shares_owned_after: 802,742.00 | Footnotes: F2
• Acquired 120,000 shares of Performance Stock Units (Derivative)
  Date: 2026-08-14 | Code: A | equity_swap_involved: 0 | shares_owned_after: 120,000.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3

Footnotes:

• F1: 25% of the total number of restricted stock units vests on the first day of the month following each of the first, second, third and fourth anniversaries of the grant date.
• F2: The Reporting Person holds all voting and dispositive power with respect to the securities held by the trusts and is the beneficial owner of these securities.
• F3: Each performance stock unit represents a contingent right to receive one share of Celcuity Inc. (the "Company") common stock. The performance stock units vest upon the Company's common stock achieving certain specified trailing average per share price thresholds.